Explanation of medical insurance reimbursement conditions for Maribavir

Maribavir (Maribavir) is one of the first-choice drugs to treat cytomegalovirus (CMV) infection, especially for patients who are resistant to other commonly used treatments such as ganciclovir, valganciclovir, cidofovir or foscarnet. Since long-term use of these drugs may lead to resistance or intolerance, maribavivir has become an important option for subsequent treatment.

In China, maribabavir has been approved and included in the scope of medical insurance reimbursement. According to relevant regulations of medical insurance, the reimbursement indications for maribavi mainly include adult patients after hematopoietic stem cell transplantation or solid organ transplantation, especially those with CMV infection and/or related diseases. In addition, these patients must show resistance or intolerance to at least one or more traditional CMV antiviral drugs, such as ganciclovir, valganciclovir, cidofovir, or foscarnet, in order to be eligible for medical insurance reimbursement.

CMV infection is a common and serious complication in immunosuppressed patients, especially those after organ transplantation or stem cell transplantation. Patients undergoing immunosuppressive therapy have suppressed immune systems and are susceptible to various viral infections, among which cytomegalovirus (CMV) is the most common causative agent. Although traditional treatment methods are effective, drug resistance problems gradually appear as the time of use increases, limiting the sustainability of the treatment effect. Maribavir, as a new type of anti-CMV drug, provides a new treatment option for these patients by targeting the specific enzyme of CMV, inhibiting its replication and reducing the spread of the virus in the body.

The implementation of the medical insurance reimbursement policy makes it easier for patients who need to use maribavir to obtain treatment with this drug. The coverage of medical insurance not only reduces the financial burden of patients, but also ensures that they can receive continuous drug support during treatment, improving the accessibility and overall effect of treatment.

Reference materials:https://www.livtencity.com/